BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma

References

• Nabhan C, Zhou X, Day BM, et al. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am J Hematol. 2016;91:770–775.
   PubMed Web of Science ®Google Scholar
• Riihijärvi S, Taskinen M, Jerkeman M, et al. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol. 2011;86:124–128.
   PubMed Web of Science ®Google Scholar
• Hirayama Y, Ishitani K, Ota S, et al. Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group. Int J Hematol. 2014;100:281–289.
   PubMed Web of Science ®Google Scholar
• Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18:1–528.
   PubMed Web of Science ®Google Scholar
• O'Connor L, Strasser A, O'Reilly LA, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. Embo J. 1998;17:384–395.
   PubMed Web of Science ®Google Scholar
• Sionov RV, Vlahopoulos SA, Granot Z. Regulation of Bim in health and disease. Oncotarget. 2015;6:23058–23134.
   PubMed Web of Science ®Google Scholar
• Ebi H, Oze I, Nakagawa T, et al. Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. J Thorac Oncol. 2015;10:59–66.
   PubMed Web of Science ®Google Scholar
• Katagiri S, Umezu T, Ohyashiki JH, et al. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients. Br J Haematol. 2013;160:269–271.
   PubMed Web of Science ®Google Scholar
• Miyamura K, Miyamoto T, Tanimoto M, et al. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. Leuk Res. 2016;51:11–18.
   PubMed Web of Science ®Google Scholar
• Lin CH, Shen CY, Lee JH, et al. High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country. PLoS One. 2015;10:e0124908.
   PubMed Web of Science ®Google Scholar
• Soh SX, Lim JY, Huang JW, et al. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia. PLoS One. 2014;9:e103435.
   PubMed Web of Science ®Google Scholar
• Jing D, Bhadri VA, Beck D, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood. 2015;125:273–283.
   PubMed Web of Science ®Google Scholar
• Huang M, Miyake K, Kagami K, et al. Lack of association between deletion polymorphism of BIM gene and in vitro drug sensitivity in B-cell precursor acute lymphoblastic leukemia. Leuk Res. 2017;60:24–30.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang Y, Zhou L, et al. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 2014;124:2687–2697.
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Tadokoro K, Yamaguchi T, et al. Detection of BIM (BCL2L11) polymorphic variants in chronic myeloid leukemia by Q-Invader assay and their clinical significance. J Hematol Transfus. 2014;2:1032.
   Google Scholar
• Lee JK, Shin JY, Kim S, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. 2013;24:2080–2087.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lin YL, Hsu WH, et al. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9:1385–1392.
   PubMed Web of Science ®Google Scholar
• Isobe K, Hata Y, Tochigi N, et al. Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation. J Thorac Oncol. 2014;9:483–487.
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhang Y, Cai W, et al. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 2014;120:2299–2307.
   PubMed Web of Science ®Google Scholar
• Zhong J, Li ZX, Zhao J, et al. Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients. Thorac Cancer. 2014;5:509–516.
   PubMed Web of Science ®Google Scholar
• Lee JY, Ku BM, Lim SH, et al. The BIM deletion polymorphism and its clinical implication in patients with EGFR-mutant non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2015;10:903–909.
   PubMed Web of Science ®Google Scholar
• Lim RB, Loy EY, Lim GH, et al. Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: secular trends of a population-based cancer registry from 1998 to 2012. Int J Cancer. 2015;137:2674–2687.
   PubMed Web of Science ®Google Scholar
• Scatizzi JC, Hutcheson J, Pope RM, et al. Bim-Bcl-2 Homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis. Arthritis Rheum. 2010;62:441–451.
   PubMedGoogle Scholar
• Nakagawa T, Takeuchi S, Yamada T, et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 2013;73:2428–2434.
   PubMed Web of Science ®Google Scholar